Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

A new gene-editing technique enables the correction of multiple genetic mutations simultaneously, transforming the prospects ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

This Collection supports and amplifies research related to SDG 2 - Zero hunger, SDG-3 (Good health and well-being), SDG-12 (Responsible consumption and production), and SDG-13 (Climate Action). CRISPR ...

A new study has revealed that the gene HMGN1 is a key driver of congenital heart defects (CHDs) in Down syndrome. Using ...

VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, Inc. for the use of select CRISPR-based ...

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...

When a neuron in our body gets damaged, segments of RNA produce proteins that can help repair the injury. But in neurological disorders such as ALS and spinal muscular atrophy, or following spinal ...

Cathie Wood's ARK Invest bought $17M in CRISPR and Beam gene-editing stocks while selling Teradyne, Roku, and SoFi shares on ...

The Cambridge-based biotech company is studying the use of Crispr, the Nobel Prize-winning gene-editing technology, to treat ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $55.16, demonstrating a -2.56% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily ...